Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 May;10(5):711-28.
doi: 10.1586/ern.10.29.

Current therapeutic targets for the treatment of Alzheimer's disease

Joshua D Grill  1 , Jeffrey L Cummings
Affiliations
Review

Current therapeutic targets for the treatment of Alzheimer's disease

Joshua D Grill et al. Expert Rev Neurother. 2010 May.

Abstract

Alzheimer's disease is a progressive neurodegenerative disease for which no cure exists. There is a substantial need for new therapies that offer improved symptomatic benefit and disease-slowing capabilities. In recent decades there has been substantial progress in understanding the molecular and cellular changes associated with Alzheimer's disease pathology. This has resulted in identification of a large number of new drug targets. These targets include, but are not limited to, therapies that aim to prevent production of or remove the amyloid-beta protein that accumulates in neuritic plaques; to prevent the hyperphosphorylation and aggregation into paired helical filaments of the microtubule-associated protein tau; and to keep neurons alive and functioning normally in the face of these pathologic challenges. We provide a review of these targets for drug development.

PubMed Disclaimer

Figures

Figure
Figure
Pathological cascade of AD. (Aß – amyloid beta protein; APP – amyloid precursor protein; IDE – insulin degrading enzyme; LTP – long term potentiation; NFT – neurofibrillary tangle; p-tau – phosphorylated tau protein).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Arch Intern Med. 9. Vol. 158. Donepezil Study Group; 1998. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. pp. 1021–1031. - PubMed
    1. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000;10(3):195–203. - PubMed
    1. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001;49(12):1590–1599. - PubMed
    1. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. Neurology. 12. Vol. 54. The Galantamine USA-10 Study Group; 2000. A 5-month, randomized, placebo-controlled trial of galantamine in AD. pp. 2269–2276. - PubMed
    1. Rosler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Bmj. 1999;318(7184):633–638. - PMC - PubMed

Web References

    1. www.clinicaltrials.gov.

MeSH terms